Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, shares developments in the multiple myeloma field that will be discussed at ASH 2020. This includes a focus on BCMA-targeted therapies, both targeted CAR-T cells and bispecific antibodies, as well as novel targets and therapeutics such as talquetamab. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.